Brokerage firm Jefferies Upgrades its rating on AstraZeneca plc (ADR)(NYSE:AZN). The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by Jefferies was issued on Sep 12, 2016.
In a different note, On Aug 29, 2016, Argus Research said it Upgrades its rating on AstraZeneca plc (ADR). The shares have been rated ‘Buy’ by the firm. Argus Research said it Initiates Coverage on AstraZeneca plc (ADR), according to a research note issued on Jul 12, 2016. The shares have been rated ‘Hold’ by the firm.
AstraZeneca plc (ADR) (AZN) made into the market gainers list on Tuesdays trading session with the shares advancing 0.39% or 0.13 points. Due to strong positive momentum, the stock ended at $33.65, which is also near the day’s high of $34.06. The stock began the session at $33.98 and the volume stood at 34,29,700 shares. The 52-week high of the shares is $35.04 and the 52 week low is $26.97. The company has a current market capitalization of $85,135 M and it has 2,53,00,00,000 shares in outstanding.
AstraZeneca plc (ADR)(AZN) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.60B. Analysts had an estimated revenue of $5.68B. Earnings per share were $0.83. Analysts had estimated an EPS of $0.76.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).